Retinopathy News and Research

RSS

Ruboxistaurin shows favorable effects on kidney damage and function in people with type 2 diabetes and nephropathy

Eli Lilly and Company today announced encouraging results from a one-year pilot study examining the effect of ruboxistaurin mesylate in persons with type 2 diabetes and kidney disease (also known as "diabetic nephropathy").

12 Jun 2005

Patients with newly diagnosed type 2 diabetes should be screened for retinopathy

Diabetic retinopathy has been found in nearly 8 percent of pre-diabetic participants in the Diabetes Prevention Program (DPP), according to a report presented today at the American Diabetes Association's 65th Annual Scientific Sessions.

12 Jun 2005

New approach to inhibiting blood vessel growth or angiogenesis

A manmade protein with a tail of amino acids delivered to target cells can dramatically reduce blood vessel growth that obstructs vision or feeds a tumor, researchers have found.

31 May 2005

Common antibiotic called minocycline may slow or prevent diabetic retinopathy

The team found that minocycline, often used to treat acne, limits by about 50 percent the retinal damage caused by microglia. Microglia are cells that act as the "cleanup crew" for the Central Nervous System (CNS).

11 May 2005

Older adults with diabetes in managed care networks have higher rates of untreated eye disease

Medicare beneficiaries at high risk for eye disease due to diabetes are more likely to have unrecognized and untreated eye disease if they are enrolled in managed care than if they have fee-for-service (FFS) health insurance, according to an article in the May issue of Archives of Ophthalmology.

9 May 2005

Internet may help prevent blindness in Medicaid patients with diabetes

A Wake Forest University Baptist Medical Center team is launching a high-tech study to determine if early screening using a special camera and images transmitted over the Internet can prevent blindness in Medicaid patients with diabetes.

4 May 2005

New study to evaluate Pegasys and Copegus to treat hepatitis C in liver transplant patients

Roche has initiated a new study to evaluate treatment strategies to reduce post-transplant recurrence of hepatitis C infection with the most prescribed hepatitis C treatment combination in the U.S., Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP).

21 Mar 2005

Researchers have identified a protein called HIF-2a, which is important in retina formation

Hoping to prevent blindness in premature babies, UT Southwestern Medical Center researchers have identified a protein that responds to oxygen levels in cells and tissues and also affects the developing eye.

22 Feb 2005

Oak Ridge technology used to understand semiconductor defects helps people at risk of becoming blind

Millions of people at risk of becoming blind could one day be helped by an Oak Ridge National Laboratory technology originally intended to understand semiconductor defects.

10 Feb 2005

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

Results from two concurrent, prospective, double-blind, multi-center clinical trials show that pegaptanib (Macugen), an anti-vascular endothelial growth factor therapy, is an effective treatment for neovascular age-related macular degeneration (AMD), according to a paper in the Dec. 30 issue of the New England Journal of Medicine. Macugen was approved by the Food and Drug Administration on Dec. 17.

30 Dec 2004

Low testosterone production appears to be a common complication of type 2 diabetes in men

Moreover, results of the investigation show that this condition, known clinically as hypogonadism, is caused not by a defect in the testes, where testosterone is produced, but by improper functioning of the pituitary gland, which controls production of testosterone, or of the hypothalamus, the region of the brain that controls the pituitary.

29 Nov 2004

Scientists have determined the crystal structure of a protein kinase C (PKC) isozyme

This structure should prove extremely useful in the rational design of small molecule inhibitors of PKCÈ, which has been implicated in T-cell mediated disease processes including inflammation and autoimmunity.

19 Nov 2004

Stem cells can preserve and improve vision in eyes damaged by retinal disease

"These findings hold great promise for potential treatments for people suffering from macular degeneration, diabetic retinopathy and other retinal diseases," says Michael Young, PhD, an assistant scientist at Schepens Eye Research Institute and the lead author of the study.

18 Nov 2004

Patients with type 2 diabetes and hypertension who kept their blood pressure very tightly controlled had fewer eye disorders caused by their diabetes

According to the article, type 2 diabetes and hypertension are often associated. At age 40, approximately 32 percent of patients with type 2 diabetes are also hypertensive, and that proportion increases to 47 percent by age 60, the article states.

8 Nov 2004

Discovery of a new blindness gene

The discovery by a Leeds University scientist of a new blindness gene could help to save the sight of thousands of sufferers of retinal disease which affects premature babies as well as people over 60.

4 Nov 2004

Do cholesterol-reducing drugs decrease the risk of heart attacks and strokes in diabetics?

International researchers will, for the first time, present findings from the landmark 4D trial about whether a cholesterol-reducing drug decreases the risk of heart attacks and strokes with type 2 diabetics on dialysis at the American Society of Nephrology’s 37th Annual Meeting and Scientific Exposition in St. Louis, Missouri.

1 Nov 2004

Ruboxistaurin may reduce vision loss from diabetes-induced eye disease

Eli Lilly and Company's investigational compound ruboxistaurin may reduce vision loss from diabetes-induced eye disease, according to new analyses of previously reported data presented at the 2004 Joint Meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology in New Orleans, La.

26 Oct 2004

FDA fast tracks Genaera's drug for the treatment of wet age-related macular degeneration

Genaera Corporation has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to squalamine, an intravenously administered, first in class, small molecule anti-angiogenic drug for the treatment of "wet" age-related macular degeneration (AMD).

4 Oct 2004

Link between elevated blood sugar levels in diabetics and increased risk of life-threatening forms of cardiovascular disease

A Johns Hopkins study suggests that people with type I and type II diabetes would be well advised to monitor their blood sugar levels more than the usual twice daily to make sure that levels are not elevated over 150 milligrams per deciliter for sustained periods.

20 Sep 2004

Potential stem cells treatment for retinitis pigmentosa and other retinal degenerations

A team of researchers from The Scripps Research Institute was able to preserve visual function in mice that were genetically predisposed to developing a profound degenerative disease that destroys their retinas.

16 Sep 2004